Contact this trialFirst, we need to learn more about you.
Risankizumab vs Deucravacitinib for Psoriasis
Recruiting3 awardsPhase 4
Houston, Texas
This trial aims to enroll 336 adults with moderate chronic plaque psoriasis to study two different treatments. The participants will receive either a subcutaneous injection of risankizumab every 12 weeks
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.